Cargando…

Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England

AIM: To pilot enhanced safety surveillance of seasonal influenza vaccine meeting the European Medicines Agency (EMA) requirement to rapidly detect a significant increase in the frequency or severity of adverse events of interest (AEIs), which may indicate risk from the new season’s vaccine. STUDY DE...

Descripción completa

Detalles Bibliográficos
Autores principales: de Lusignan, Simon, Dos Santos, Gaël, Correa, Ana, Haguinet, François, Yonova, Ivelina, Lair, Florence, Byford, Rachel, Ferreira, Filipa, Stuttard, Karen, Chan, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Open 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541341/
https://www.ncbi.nlm.nih.gov/pubmed/28515198
http://dx.doi.org/10.1136/bmjopen-2016-015469
_version_ 1783254791713980416
author de Lusignan, Simon
Dos Santos, Gaël
Correa, Ana
Haguinet, François
Yonova, Ivelina
Lair, Florence
Byford, Rachel
Ferreira, Filipa
Stuttard, Karen
Chan, Tom
author_facet de Lusignan, Simon
Dos Santos, Gaël
Correa, Ana
Haguinet, François
Yonova, Ivelina
Lair, Florence
Byford, Rachel
Ferreira, Filipa
Stuttard, Karen
Chan, Tom
author_sort de Lusignan, Simon
collection PubMed
description AIM: To pilot enhanced safety surveillance of seasonal influenza vaccine meeting the European Medicines Agency (EMA) requirement to rapidly detect a significant increase in the frequency or severity of adverse events of interest (AEIs), which may indicate risk from the new season’s vaccine. STUDY DESIGN: A prospective passive enhanced safety surveillance combining data collection from adverse drug reaction (ADR) cards with automated collection of pseudonymised routinely collected electronic health record (EHR) data. This study builds on a feasibility study carried out at the start of the 2015/2016 influenza season. We will report influenza vaccine exposure and any AEIs reported via ADR card or recorded directly into the EHR, from the commencement of influenza vaccination and ends as specified by EMA (30 November 2016). SETTING: Ten volunteer English general practices, primarily using the GSK influenza vaccines. They had selected this vaccine in advance of the study. PARTICIPANTS: People who receive a seasonal influenza vaccine, in each age group defined in EMA interim guidance: 6 months to 5 years, 6–12 years, 13–17 years, 18–65 years and >65 years. OUTCOME MEASURES: The primary outcome measure is the rate of AEIs occurring within 7 days postvaccination, using passive surveillance of general practitioner (GP) EHR systems enhanced by a card-based ADR reporting system. Extracted data will be presented overall by brand (Fluarix Tetra vs others), by age strata and risk groups. The secondary outcome measure is the vaccine uptake among the subjects registered in the enrolled general practices. ETHICS AND DISSEMINATION: Ethical approval was granted by the Proportionate Review Sub-committee of the North East—Newcastle & North Tyneside 2 on 5 August 2016. The study received approval from the Health Research Authority on 1 September 2016. We will produce an interim analysis within 8 weeks, and an end-of-study report, which will be submitted to peer-reviewed journals.
format Online
Article
Text
id pubmed-5541341
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Open
record_format MEDLINE/PubMed
spelling pubmed-55413412017-08-07 Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England de Lusignan, Simon Dos Santos, Gaël Correa, Ana Haguinet, François Yonova, Ivelina Lair, Florence Byford, Rachel Ferreira, Filipa Stuttard, Karen Chan, Tom BMJ Open Epidemiology AIM: To pilot enhanced safety surveillance of seasonal influenza vaccine meeting the European Medicines Agency (EMA) requirement to rapidly detect a significant increase in the frequency or severity of adverse events of interest (AEIs), which may indicate risk from the new season’s vaccine. STUDY DESIGN: A prospective passive enhanced safety surveillance combining data collection from adverse drug reaction (ADR) cards with automated collection of pseudonymised routinely collected electronic health record (EHR) data. This study builds on a feasibility study carried out at the start of the 2015/2016 influenza season. We will report influenza vaccine exposure and any AEIs reported via ADR card or recorded directly into the EHR, from the commencement of influenza vaccination and ends as specified by EMA (30 November 2016). SETTING: Ten volunteer English general practices, primarily using the GSK influenza vaccines. They had selected this vaccine in advance of the study. PARTICIPANTS: People who receive a seasonal influenza vaccine, in each age group defined in EMA interim guidance: 6 months to 5 years, 6–12 years, 13–17 years, 18–65 years and >65 years. OUTCOME MEASURES: The primary outcome measure is the rate of AEIs occurring within 7 days postvaccination, using passive surveillance of general practitioner (GP) EHR systems enhanced by a card-based ADR reporting system. Extracted data will be presented overall by brand (Fluarix Tetra vs others), by age strata and risk groups. The secondary outcome measure is the vaccine uptake among the subjects registered in the enrolled general practices. ETHICS AND DISSEMINATION: Ethical approval was granted by the Proportionate Review Sub-committee of the North East—Newcastle & North Tyneside 2 on 5 August 2016. The study received approval from the Health Research Authority on 1 September 2016. We will produce an interim analysis within 8 weeks, and an end-of-study report, which will be submitted to peer-reviewed journals. BMJ Open 2017-05-17 /pmc/articles/PMC5541341/ /pubmed/28515198 http://dx.doi.org/10.1136/bmjopen-2016-015469 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Epidemiology
de Lusignan, Simon
Dos Santos, Gaël
Correa, Ana
Haguinet, François
Yonova, Ivelina
Lair, Florence
Byford, Rachel
Ferreira, Filipa
Stuttard, Karen
Chan, Tom
Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England
title Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England
title_full Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England
title_fullStr Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England
title_full_unstemmed Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England
title_short Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England
title_sort post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in england
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541341/
https://www.ncbi.nlm.nih.gov/pubmed/28515198
http://dx.doi.org/10.1136/bmjopen-2016-015469
work_keys_str_mv AT delusignansimon postauthorisationpassiveenhancedsafetysurveillanceofseasonalinfluenzavaccinesprotocolofapilotstudyinengland
AT dossantosgael postauthorisationpassiveenhancedsafetysurveillanceofseasonalinfluenzavaccinesprotocolofapilotstudyinengland
AT correaana postauthorisationpassiveenhancedsafetysurveillanceofseasonalinfluenzavaccinesprotocolofapilotstudyinengland
AT haguinetfrancois postauthorisationpassiveenhancedsafetysurveillanceofseasonalinfluenzavaccinesprotocolofapilotstudyinengland
AT yonovaivelina postauthorisationpassiveenhancedsafetysurveillanceofseasonalinfluenzavaccinesprotocolofapilotstudyinengland
AT lairflorence postauthorisationpassiveenhancedsafetysurveillanceofseasonalinfluenzavaccinesprotocolofapilotstudyinengland
AT byfordrachel postauthorisationpassiveenhancedsafetysurveillanceofseasonalinfluenzavaccinesprotocolofapilotstudyinengland
AT ferreirafilipa postauthorisationpassiveenhancedsafetysurveillanceofseasonalinfluenzavaccinesprotocolofapilotstudyinengland
AT stuttardkaren postauthorisationpassiveenhancedsafetysurveillanceofseasonalinfluenzavaccinesprotocolofapilotstudyinengland
AT chantom postauthorisationpassiveenhancedsafetysurveillanceofseasonalinfluenzavaccinesprotocolofapilotstudyinengland